Table 2. (Continued)
<table border=1>
<tr>
<td rowspan="2">Cell line</td>
<td colspan="10">PKC isoform</td>
</tr>
<tr>
<td>$\alpha$</td>
<td>$\beta 1/\beta 11$</td>
<td>$\gamma$</td>
<td>$\delta$</td>
<td>$\varepsilon$</td>
<td>$\eta$</td>
<td>$\theta$</td>
<td>$\zeta$</td>
<td>$\lambda/t$</td>
<td>Detection *</td>
<td>Reference</td>
</tr>
<tr>
<td>WM115 (primary)</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>W</td>
<td></td>
</tr>
<tr>
<td>WM1205La (metastatic)</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>W</td>
<td></td>
</tr>
<tr>
<td>SK-Mel 28 (metastatic)</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td>W, R</td>
<td></td>
</tr>
<tr>
<td>A375 (primary)</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td>W, R</td>
<td></td>
</tr>
<tr>
<td colspan="11">
$\mathrm{M}100000000000000000000$</td>
</tr>
<tr>
<td>B16 (metastatic)</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>B16-F1 (metastatic)</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>W</td>
<td></td>
</tr>
<tr>
<td>B16-10 (metastatic)</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>W</td>
<td></td>
</tr>
<tr>
<td>B16 (metastatic)</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>W</td>
<td></td>
</tr>
<tr>
<td>
<span>\hularular</span></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</table>* N: Northern blot, F: Flow cytometry, W: Western blot, R: Reverse transcription-polymerase chain reaction.
** Not determined.
the \(\beta\) isoform in melanocytes , and further showed that PKC inhibitor reduces pigmentation in murine skin in vivo . It is interesting to assume that the \(\beta\) isoform is indispensable for the regulation of the tyrosinase activity, but melanin is detected even in the melanoma cells lacking the PKC \(\beta\) isoform [25,27]. On the other hand, the \(\alpha\) isoform is increased in murine B16 melanoma cells treated with retinoic acid [37,, and the induction as well as the overexpression of this
PKC isoform enhances the melanin synthesis, suggesting the involvement of the \(\alpha\) isoform in melanogenesis . The level of the \(\alpha\) isoform is also elevated in B16 cells cultured with mannosylerythrititol lipid, a novel extracellular glycolipid from yeast that induces differentiation of HL-60 promyelocytic leukemia cells . The introduction of antisense oligodeoxynucleotides against the \(\alpha\) isoform prevented mannosylerythrititol lipid-induced melanogenesis, and the expression of the
Table 3. The expression of PKC isoforms in human melanoma cells in vivo
<table border=1>
<tr>
<td rowspan="2">Origin</td>
<td colspan="12">PKC isoform</td>
</tr>
<tr>
<td colspan="12">PKC isoform</td>
</tr>
<tr>
<td>(2)</td>
<td>Clinical type*</td>
<td>$\alpha$</td>
<td>$\beta 1/\beta 11$</td>
<td>$y$</td>
<td>$\delta$</td>
<td>$\varepsilon$</td>
<td>$\eta$</td>
<td>$g$</td>
<td>$\zeta$</td>
<td>$\lambda/t$</td>
<td>Detection**</td>
<td>Reference</td>
</tr>
<tr>
<td>Primary</td>
<td>ALM</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>ND***</td>
<td>ND</td>
<td>ND</td>
<td>W</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metastatic</td>
<td>Unknown</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>+</td>
<td>ND</td>
<td>W</td>
<td></td>
</tr>
<tr>
<td>Metastatic</td>
<td>NS (5 cases)</td>
<td>ND</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>I</td>
<td></td>
</tr>
<tr>
<td>Metastatic</td>
<td>NS (5 cases)</td>
<td>ND</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>I</td>
<td></td>
<td></td>
</tr>
<tr>
<td>
<span>\htabular</span>—l—
Metastatic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metastatic</td>
<td>NS (5 cases)</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>W</td>
<td></td>
</tr>
<tr>
<td>Metastatic</td>
<td>ALM (2 cases)</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>W</td>
<td></td>
</tr>
<tr>
<td>Primary</td>
<td>ALM</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>I</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary</td>
<td>ALM (11 cases)</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary</td>
<td>SSM (7 cases)</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>I</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metastatic</td>
<td>ALM (2 cases)</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>$\mathrm{I}$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metastatic</td>
<td>SSM (2 cases)</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
</tr>
</table>*ALM: acral lentiginous melanoma: SSM: superficial spreading melanoma, NS: not stated.
**W: Western blot, I: immunohistochemistry.
***No determined.